🇺🇸 FDA
Pipeline program

VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

CVAY736F12302

Phase 3 small_molecule active

Quick answer

VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , - for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Systemic Lupus Erythematosus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials